Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00855465 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
A Phase 3 study of Pulmonary Hypertension, sponsored by Bayer.
- Completed
- Registry status
- Phase 3
- Development phase
- 262
- Enrollment target
- 20
- Study locations
NCT00855465 is a Phase 3 study of Pulmonary Hypertension that has completed, run by Bayer. The registered enrollment target is 262 participants, below the 610-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (57% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT00855465, a Phase 3 study of Pulmonary Hypertension, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 262 participants
- Enrollment target
- 20
- Study locations
Study Summary
The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Riociguat (Adempas, BAY63-2521)
Study Locations (20)
Other
- - Corrientes
- - Innsbruck
- - Vienna
- - Bruxelles - Brussel
- - Leuven
- - Rio de Janeiro
California
- - La Jolla
- - Sacramento
Ohio
- - Cleveland
- - Columbus
Florida
- - Miami
Iowa
- - Iowa City
Maryland
- - Baltimore
Massachusetts
- - Boston
Texas
- - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 262 participants |
| Start Date | 2009-02-23 |
| Est. Completion | 2012-06-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00855465
The ClinicalTrials.gov registry entry for NCT00855465 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 262 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 610-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (57% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pulmonary Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00855465 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, California, Ohio.
Frequently Asked Questions
What is clinical trial NCT00855465 about?
NCT00855465 is a clinical study titled "A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.". The aim of the study is to assess the efficacy and safety of different doses of BAY63-2521, given orally for 16 weeks, in patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH).
What is the current status of trial NCT00855465?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 262 participants. The study started on 2009-02-23. Estimated completion is 2012-06-27.
What conditions does trial NCT00855465 study?
This clinical trial studies the following conditions: Pulmonary Hypertension.
What interventions are being tested in trial NCT00855465?
The interventions under investigation include: Placebo (DRUG), Riociguat (Adempas, BAY63-2521) (DRUG).
Who is sponsoring clinical trial NCT00855465?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00855465 being conducted?
This trial has 20 study locations across California, Florida, Iowa, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
RECRUITING · Phase 3
-
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RECRUITING · Phase 3
-
Safety and Efficacy of FETO in CDH Phase III
RECRUITING · Phase 3
-
Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
COMPLETED · Phase 3
-
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
COMPLETED · Phase 3
-
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.